Therapeutic potentials of nonpeptidic V2R agonists for partial cNDI-causing V2R mutants
PLOS ONE · 15.05.2024 · 19 (5) · e0303507
DOI: 10.1371/journal.pone.0303507 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 15.05.2024. Verfasst von Ritsuki Kuramoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan. Hauptthemen laut MEDLINE: Diabetes Insipidus, Nephrogenic, Receptors, Vasopressin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Loss-of-function mutations in the type 2 vasopressin receptor (V2R) are a major cause of congenital nephrogenic diabetes insipidus (cNDI). In the context of partial cNDI, the response to desmopressin (dDAVP) is partially, but not entirely, diminished. For those with the partial cNDI, restoration of V2R function would offer a prospective therapeutic approach. In this study, we revealed that OPC-51803 (OPC5) and its structurally related V2R agonists could functionally restore V2R mutants causing partial cNDI by inducing prolonged signal activation. The OPC5-related agonists exhibited functional selectivity by inducing signaling through the G s -cAMP pathway while not recruiting β-arrestin1/2. We found that six cNDI-related V2R partial mutants (V88 2.53 M, Y128 3.41 S, L161 4.47 P, T273 6.37 M, S329 8.47 R and S333 8.51 del) displayed varying degrees of plasma membrane expression levels and exhibited moderately impaired signaling function. Several OPC5-related agonists induced higher cAMP responses than AVP at V2R mutants after prolonged agonist stimulation, suggesting their potential effectiveness in compensating impaired V2R-mediated function. Furthermore, docking analysis revealed that the differential interaction of agonists with L312 7.40 caused altered coordination of TM7, potentially contributing to the functional selectivity of signaling. These findings suggest that nonpeptide V2R agonists could hold promise as potential drug candidates for addressing partial cNDI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan.
- Division of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Kouki Kawakami, Tatsuya Ikuta, Asuka Inoue
Förderung
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
- Japan Agency for Medical Research and Development
Zitieren
APA
Kuramoto, R., Kise, R., Kanno, M., Kawakami, K., Ikuta, T., Makita, N., & Inoue, A. (2024). Therapeutic potentials of nonpeptidic V2R agonists for partial cNDI-causing V2R mutants. PLOS ONE, 19(5), e0303507. https://doi.org/10.1371/journal.pone.0303507
Vancouver
Kuramoto R, Kise R, Kanno M, Kawakami K, Ikuta T, Makita N, et al. Therapeutic potentials of nonpeptidic V2R agonists for partial cNDI-causing V2R mutants. PLOS ONE. 2024;19(5):e0303507. doi:10.1371/journal.pone.0303507
BibTeX
@article{Kuramoto2024,
author = {Kuramoto, Ritsuki and Kise, Ryoji and Kanno, Mayu and Kawakami, Kouki and Ikuta, Tatsuya and Makita, Noriko and Inoue, Asuka},
title = {Therapeutic potentials of nonpeptidic V2R agonists for partial cNDI-causing V2R mutants},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {5},
pages = {e0303507},
doi = {10.1371/journal.pone.0303507}
}
EUVIMED